Nazzareno Dimasi, Ph.D.
Nazzareno Dimasi, Ph.D.
Senior Director, Head of Antibody Discovery, Biologics Research USA
Verified email at - Homepage
Cited by
Cited by
STRUCTURE AND FUNCTION OF NATURAL KILLER CELL RECEPTORS: Multiple Molecular Solutions to Self, Nonself Discrimination
K Natarajan, N Dimasi, J Wang, RA Mariuzza, DH Margulies
Annual review of immunology 20 (1), 853-885, 2002
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
A DiGiandomenico, AE Keller, C Gao, GJ Rainey, P Warrener, ...
Science Translational Medicine 6 (262), 262ra155-262ra155, 2014
A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy
JY Li, SR Perry, V Muniz-Medina, X Wang, LK Wetzel, MC Rebelatto, ...
Cancer cell 29 (1), 117-129, 2016
Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K b
J Dam, R Guan, K Natarajan, N Dimasi, LK Chlewicki, DM Kranz, ...
Nature immunology 4 (12), 1213-1222, 2003
Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II
Y Li, H Li, N Dimasi, JK McCormick, R Martin, P Schuck, PM Schlievert, ...
Immunity 14 (1), 93-104, 2001
Affinity selection of a camelized V (H) domain antibody inhibitor of hepatitis C virus NS3 protease.
F Martin, C Volpari, C Steinkuhler, N Dimasi, M Brunetti, G Biasiol, ...
Protein Engineering 10 (5), 607-614, 1997
Human natural killer cell receptors: insights into their molecular function and structure
R Biassoni, C Cantoni, D Marras, J Giron‐Michel, M Falco, L Moretta, ...
Journal of cellular and molecular medicine 7 (4), 376-387, 2003
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences
JCD Houtman, Y Higashimoto, N Dimasi, S Cho, H Yamaguchi, ...
Biochemistry 43 (14), 4170-4178, 2004
Structural and functional aspects of the Ly49 natural killer cell receptors
N Dimasi, R Biassoni
Immunology and cell biology 83 (1), 1-8, 2005
Structural basis of MHC class I recognition by natural killer cell receptors
MW Sawicki, N Dimasi, K Natarajan, J Wang, DH Margulies, RA Mariuzza
Immunological reviews 181 (1), 52-65, 2001
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators
N Dimasi, C Gao, R Fleming, RM Woods, XT Yao, L Shirinian, PA Kiener, ...
Journal of molecular biology 393 (3), 672-692, 2009
Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin
L Musante, G Candiano, A Petretto, M Bruschi, N Dimasi, G Caridi, ...
Journal of the American Society of Nephrology 18 (3), 799-810, 2007
Multispecific epitope binding proteins and uses thereof
H Wu, C Gao, C Hay, N Dimasi
US Patent App. 12/182,975, 2009
Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides
RJ Christie, R Fleming, B Bezabeh, R Woods, S Mao, J Harper, A Joseph, ...
Journal of Controlled Release 220, 660-670, 2015
Characterization of oxidation end product of plasma albumin ‘in vivo’
L Musante, M Bruschi, G Candiano, A Petretto, N Dimasi, P Del Boccio, ...
Biochemical and biophysical research communications 349 (2), 668-673, 2006
Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
N Dimasi, F Martin, C Volpari, M Brunetti, G Biasiol, S Altamura, R Cortese, ...
Journal of Virology 71 (10), 7461-7469, 1997
Expression, crystallization and X-ray data collection from microcrystals of the extracellular domain of the human inhibitory receptor expressed on myeloid cells IREM-1
N Dimasi, D Flot, F Dupeux, JA Márquez
Acta Crystallographica Section F: Structural Biology and Crystallization …, 2007
Design of selective eglin inhibitors of HCV NS3 proteinase
F Martin, N Dimasi, C Volpari, C Perrera, S Di Marco, M Brunetti, ...
Biochemistry 37 (33), 11459-11468, 1998
Efficient preparation of site-specific antibody–drug conjugates using cysteine insertion
N Dimasi, R Fleming, H Zhong, B Bezabeh, K Kinneer, RJ Christie, ...
Molecular pharmaceutics 14 (5), 1501-1516, 2017
Antibody–drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies
J Rios-Doria, J Harper, R Rothstein, L Wetzel, J Chesebrough, A Marrero, ...
Cancer research 77 (10), 2686-2698, 2017
The system can't perform the operation now. Try again later.
Articles 1–20